By Assoc. Prof. Dr. Mehmet Sorar | Published: 05.02.2025
Alzheimer TMS Therapy: Investigational, Not FDA-Cleared
Transcranial magnetic stimulation (TMS) for Alzheimer's disease is investigational. The US Food and Drug Administration (FDA) has not cleared it: in 2019 an advisory panel voted 14 to 0 against recommending the neuroAD device, which combines TMS with cognitive exercises, and the request was denied. Small trials and meta-analyses report possible modest benefit, but results vary widely and TMS has not been shown to treat or slow the disease.
Is TMS cleared for Alzheimer's disease?
No, not in the United States. The 2022 FDA timeline by Cohen and colleagues records that the De Novo request (a US route for new types of device) for the neuroAD system, which pairs TMS with computer-based cognitive training, was denied in 2019. The Cleveland Clinic names four FDA-cleared uses of TMS, and Alzheimer's disease is not one of them.
Practical Neurology reported at the time that the device was already approved in Europe, Australia and Israel. Approval in another country does not by itself show that a treatment works. The full list of conditions with clearance, and those without, is on the page about what TMS is.
What did the FDA panel find about neuroAD?
As Practical Neurology reported, the FDA's advisory panel voted 14 to 0 against recommending approval. The main concern was effectiveness: the pivotal trial showed smaller gains on cognitive test scores than sham treatment, which is a fake treatment that feels like the real one. FDA reviewers also raised concerns about the study methods and analysis, including the pooling of data from studies in Israel and the US.
The panel had no safety concerns, so the decision was about whether the device worked, not whether it caused harm. It concerned one device and one trial design. It did not test every TMS protocol.
What do trials and meta-analyses show?
Results depend heavily on which trials are pooled and how. Two meta-analyses show the range:
- Wei and colleagues (2022) pooled 14 studies with 513 people with Alzheimer's disease. The effect on global cognition was small to moderate, roughly 0.2 to 0.3 on a standardised scale where larger numbers mean larger effects. Daily living improved in 3 studies (0.64), but memory, executive function and mood scores did not change significantly. Differences between trials were large, publication bias (positive results being more likely to reach print) was suggested, and follow-up was mostly 1 to 3 months. The authors call the total sample small and advise caution.
- Pagali and colleagues (2024, Mayo Clinic) covered 143 studies with 5,800 people. Their meta-analysis of 25 randomised trials in mild cognitive impairment and Alzheimer's disease found much larger pooled effects, for example 0.80 on the MMSE, a common test of memory and thinking. The abstract notes significant differences between the trials.
With results ranging from small to large, no single figure should be quoted as the effect of TMS in Alzheimer's disease. Only 6 studies in the Wei analysis assessed effects after treatment ended, so how long any benefit lasts is unknown, and the Pagali abstract does not say whether the benefit is clinically meaningful or lasting. In the Wei analysis, subgroups with 10 Hz stimulation, a single left prefrontal target, 20 or more sessions and follow-up beyond 6 weeks looked better. The trials in that analysis differed widely, so these subgroups are not recommended settings. Adding cognitive training did not give a significant extra benefit.
How risky is TMS for someone with Alzheimer's disease, and who is excluded?
In the two meta-analyses, side effects were mostly mild. In the Wei analysis four studies reported adverse events, mainly scalp discomfort and headache, and two people had temporary tiredness. No seizures were recorded, but the authors urge caution in people with a seizure history. In the Pagali analysis only 2 of 143 studies reported seizures, 4 events in total. Three were judged unrelated to TMS and one resolved after the coil was repositioned. The authors call TMS well tolerated with infrequent serious events.
The Cleveland Clinic names headache, scalp discomfort and mild facial twitching as the common side effects. Seizure is the most serious and is very rare, and the risk is higher with epilepsy, a seizure history or medicines that lower the seizure threshold. It also says TMS does not cause memory loss or thinking problems. This statement concerns TMS in general. TMS is not given, or needs particular care, in people with:
- Metal or electronic implants in the head or neck that cannot be removed, such as cochlear implants, aneurysm clips or coils, implanted brain stimulators, metal plates or shrapnel.
- A pacemaker or defibrillator.
- Epilepsy or a seizure history, where the provider may change medicines or suggest another treatment.
The team should know about every medicine in use. Do not change Alzheimer's medicines without the doctor who prescribes them. Seizure figures from different sources are compared on the page about TMS safety data.
What should you ask if TMS is offered for Alzheimer's disease?
Because TMS is investigational here, the questions below matter more than usual. The aim is to base the decision on evidence rather than on a device's promotion:
- Is this a research programme or a service sold to patients?
- Which published study supports this protocol, and how many people took part and for how long?
- Which brain region will be stimulated, and how many sessions over how many weeks? The page on how TMS protocols are built explains these settings.
- How and when will thinking and daily function be measured?
- Have seizure history, medicines and implants been checked?
- Who runs the sessions, and when will they stop if no benefit appears? More criteria are in the guide to choosing a TMS doctor in Ankara.
When do memory and thinking changes need a doctor's assessment?
New or worsening problems with memory, planning, language or looking after yourself call for a medical assessment before any TMS is considered. The NHS says the first sign of Alzheimer's disease is usually minor memory problems. Later signs can include confusion, trouble with planning and decisions, language problems, difficulty with self-care, changes in behaviour, hallucinations and delusions, and low mood or anxiety.
According to the NHS, no single test diagnoses it. A GP rules out other causes, and a specialist service arranges assessments and scans. The NHS also states that there is currently no cure and that medicines can relieve some symptoms. A seizure during or after a TMS session needs emergency care.
Sources
- Practical Neurology (news report, 2019): FDA advisory panel review of transcranial magnetic stimulation plus cognitive training for Alzheimer's disease
- Cohen et al.: A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices, Brain Stimulation 2022
- Wei et al.: The therapeutic efficacy of transcranial magnetic stimulation in managing Alzheimer's disease: A systematic review and meta-analysis, Frontiers in Aging Neuroscience 2022
- Pagali et al.: Efficacy and safety of transcranial magnetic stimulation on cognition in mild cognitive impairment, Alzheimer's disease, Alzheimer's disease-related dementias, and other cognitive disorders: a systematic review and meta-analysis, International Psychogeriatrics 2024
- Cleveland Clinic: Transcranial Magnetic Stimulation (TMS)
- NHS: Alzheimer's disease
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: TMS Tedavisi